MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
74.2 M |
Market Cap[1] |
$ 2.52 B |
EBITDA (LTM) |
$ -145 M |
P/E (LTM) |
-22.261146 |
P/S (LTM) |
12.9413 |
EPS (LTM) |
-1.57 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Satsuma Pharmaceuticals
STSA
|
- | -0.9 % | $ 36.5 M | Nasdaq Global Market | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
$ 1.1 | -12.7 % | $ 93.8 M | Nasdaq Capital Market | USA |
 |
SpringWorks Therapeutics
SWTX
|
- | - | $ 3.48 B | Nasdaq Global Select Market,SPB | USA |
 |
Metacrine
MTCR
|
- | - | $ 24.2 M | Nasdaq Global Select Market | USA |
 |
Turning Point Therapeutics
TPTX
|
- | -0.13 % | $ 3.73 B | Nasdaq Global Select Market,SPB | USA |
 |
Infinity Pharmaceuticals
INFI
|
- | -46.98 % | $ 3.57 M | Nasdaq Global Select Market | USA |
 |
OncoSec Medical Incorporated
ONCS
|
- | 31.87 % | $ 1.61 M | Nasdaq Global Select Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
Evelo Biosciences
EVLO
|
- | -14.46 % | $ 27.9 M | Nasdaq Global Select Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Morphic Holding
MORF
|
- | - | $ 2.42 B | Nasdaq Global Market | USA |
 |
Novan
NOVN
|
- | -24.84 % | $ 2.64 M | Nasdaq Capital Market | USA |
 |
Genocea Biosciences
GNCA
|
- | -15.0 % | $ 3.04 M | Nasdaq Global Select Market | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
- | -9.21 % | $ 2.55 M | Nasdaq Global Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
BELLUS Health
BLU
|
- | - | $ 2.47 B | Nasdaq Global Select Market |  Canada |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Intra-Cellular Therapies
ITCI
|
- | - | $ 13.6 B | Nasdaq Global Select Market,SPB | USA |
 |
IGM Biosciences
IGMS
|
- | - | $ 76.9 M | Nasdaq Global Select Market,SPB | USA |
 |
Marinus Pharmaceuticals
MRNS
|
- | - | $ 29.6 M | Nasdaq Global Select Market | USA |
 |
Merrimack Pharmaceuticals
MACK
|
- | - | $ 216 M | Nasdaq Global Market | USA |
 |
CASI Pharmaceuticals
CASI
|
- | - | $ 35.4 M | Nasdaq Capital Market | USA |
 |
ContraFect Corporation
CFRX
|
- | -5.16 % | $ 5.39 M | Nasdaq Capital Market | USA |
 |
Sigilon Therapeutics
SGTX
|
- | - | $ 728 M | Nasdaq Global Select Market | USA |
 |
Rubius Therapeutics
RUBY
|
- | -33.55 % | $ 7.81 M | Nasdaq Global Select Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
TRACON Pharmaceuticals
TCON
|
- | -1.38 % | $ 46.8 M | Nasdaq Capital Market | USA |
 |
Mirati Therapeutics
MRTX
|
- | - | $ 3.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Revance Therapeutics
RVNC
|
- | - | $ 309 M | Nasdaq Global Select Market | USA |
 |
Allogene Therapeutics
ALLO
|
$ 1.09 | -8.82 % | $ 240 M | Nasdaq Global Select Market,SPB | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
- | -37.48 % | $ 476 K | Nasdaq Capital Market | USA |
 |
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.86 | -4.07 % | $ 2.44 M | Nasdaq Global Select Market | USA |
 |
Forward Pharma A/S
FWP
|
- | -0.75 % | $ 18.7 M | Nasdaq Capital Market |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
- | 1.02 % | $ 90.8 M | Nasdaq Global Select Market |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
- | - | $ 154 M | Nasdaq Capital Market | USA |
 |
Oyster Point Pharma
OYST
|
- | - | $ 300 M | Nasdaq Global Select Market | USA |
 |
Nabriva Therapeutics plc
NBRV
|
- | - | $ 4.55 M | Nasdaq Global Select Market |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
- | - | $ 643 M | Nasdaq Global Select Market,SPB | USA |
 |
NGM Biopharmaceuticals
NGM
|
- | - | $ 127 M | Nasdaq Global Select Market,SPB | USA |
 |
Regulus Therapeutics
RGLS
|
- | - | $ 155 M | Nasdaq Global Select Market | USA |
 |
9 Meters Biopharma
NMTR
|
- | -42.97 % | $ 1.05 M | Nasdaq Global Select Market | USA |
 |
Chinook Therapeutics
KDNY
|
- | - | $ 2.6 B | Nasdaq Global Select Market | USA |
 |
Lumos Pharma
LUMO
|
- | - | $ 35.3 M | Nasdaq Global Select Market | USA |
 |
Syros Pharmaceuticals
SYRS
|
- | -8.44 % | $ 3.4 M | Nasdaq Global Select Market | USA |
 |
Gamida Cell Ltd.
GMDA
|
- | -18.25 % | $ 5.04 M | Nasdaq Global Market | Israel |
 |
GT Biopharma
GTBP
|
$ 4.5 | -7.02 % | $ 24.8 M | Nasdaq Capital Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.